Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance
Mawad R, Gopal A.K., Press O.W., et al.
Key Points:
Investigators studied fludarabine, cyclophosphamide, rituximab, vorinostat (FCR+V) followed by maintenance therapy with rituximab and vorinostat in previously untreated CLL/SLL
Median follow-up: 15 months (range, 0.9-38.6)
22/36 enrolled patients evaluable
Complete response (CR): 73%, Partial response (PR): 22.5%, Stable disease (SD): 4.5%
18% completed 8 cycles of maintenance with rituximab and vorinostat
Grade 3-4 non-hematologic toxicities: gastrointestinal symptoms (n=10) and fatigue (n=3).
Implications:
- Treatment of CLL/SLL with fludarabine, cyclophosphamide, rituximab and vorinostat followed by maintenance with rituximab and vorinostat feasible and tolerable, may warrant further study.
View the original abstract on the ASH website.
